Category: 2077-19-2

With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, molecular weight is 215.09, as common compound, the synthetic route is as follows.HPLC of Formula: C9H11BrO

tert-Butyldimethylsilyl chloride (2.1O g, 14 mmol) was added to a mixture of 2-(4-bromophenyl)-propan-2-ol (2.0 g, 9.3 mmol) and imidazole (0.95 g 14 mmol) in DMF (30 mL) and the resultant mixture was stirred at 80 C for 24 h. The mixture was concentrated to one third of the original volume then diluted with water (50 mL) and extracted with diethyl ether (3 x 50 mL). The combined organic layer was dried over anhydrous sodium sulfate, filtered and evaporated in vacuo. The resultant residue was purified by chromatography (silica, 5Og column, Si-SPE, 0-5% diethyl ether in pentane) to afford the title compound as a colourless oil (1.39 g, 46%). 1H NMR (MeOD, 400MHz): 7.46-7.37 (m, 4H); 1.56 (s, 6H); 0.95-0.91 (m, 9H); 0.06 (s, 6H).

At the same time, in my other blogs, there are other synthetic methods of this type of compound,2077-19-2, 2-(4-Bromophenyl)propan-2-ol, and friends who are interested can also refer to it.

Reference:
Patent; GENENTECH, INC.; WO2009/151598; (2009); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, molecular weight is 215.09, as common compound, the synthetic route is as follows.category: alcohols-buliding-blocks

[0001250] A mixture of 2-(4-bromophenyl)propan-2-ol (49 mg, 0.23 mmol), Compound 296B (110 mg, 0.23 mmol), [1 J’-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (8.4 mg, 10 muiotaetaomicron), potassium carbonate (49 mg, 0.46 mmol), water (1 mL), and 1,4-dioxane (5 mL) was heated under nitrogen atmosphere at 100 C for 2 h. After cooling, water (5 mL) was added, and the mixture was extracted with ethyl acetate (10 mL x 3). The combined organic layers were washed with brine (5 mL). The combined organic layers were dried over anhydrous sodium sulfate, filtered, and concentrated to afford the crude product as a black oil. The oil was purified with prep-HPLC. The solution was adjusted to pH = 8.0 with sodium bicarbonate solution, extracted with ethyl acetate (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to furnish Compound 358. LC-MS (ESI) m/z: 577 [M+H]+; 1H-NMR (CDCI3, 400 MHz): delta (ppm) 0.76-0.88 (m, 4H), 1.23-1.30 (m, 1H), 1.63 (s, 6H), 1.83-1.88 (m, 4H), 2.01 (s, 1H), 2.73-2.81 (m, 5H), 2.97-3.03 (m, 2H), 3.74-3.79 (m, 1H), 4.33 (d, J= 4.4 Hz, 1H), 5.11 (d, J= 2.4 Hz, 1H), 7.21-7.28 (m, 1H), 7.35-7.51 (m, 3H), 7.57-7.63 (m, 4H), 7.68 (d, J= 7.2 Hz, 2H), 8.26 (d, J= 8.8 Hz, 1H).

At the same time, in my other blogs, there are other synthetic methods of this type of compound,2077-19-2, 2-(4-Bromophenyl)propan-2-ol, and friends who are interested can also refer to it.

Reference:
Patent; BIOMARIN PHARMACEUTICAL INC.; WANG, Bing; CHU, Daniel; BRIDGES, Alexander, James; WO2015/42397; (2015); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

The major producers of chemicals have been the Europe, Japan and China. Due to the growing call for a cleaner, greener environment, people will have to find innovative ways to maintain their relevance. Here is a compound 2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol. This compound has unique chemical properties. The synthetic route is as follows. Recommanded Product: 2-(4-Bromophenyl)propan-2-ol

To a suspension of 2-(4-bromo-phenyl)-propan-2-ol (1.00 g, 4.65 mmol), copper(l) iodide (177 mg, 0.93 mmol) and sodium (2R)-2-[(2R)-3,4-dihydroxy- 5-oxo-2H-furan-2-yl]-2-hydroxy-ethanolate hydrate (100 mg, 0.46 mmol in amixture of DMF (4 ml) and water (5 ml) are added sodium azide (605 mg, 9.3 mmol) and N,N?-dimethyl-ethane-1,2-diamine (123 mg, 1.39 mmol). The reaction mixture is stirred at room temperature for 19 hours. The reaction mixture is poured into 40 ml saturated aqueous sodium chloride solution. The mixture is extracted with ethyl acetate. The organic phase is dried over sodium sulfate and evaporated. The residue is chromatographed on a silica gel column with cyclohexane/ethyl acetate as eluent to afford 2-(4-azido-phenyl)- propan-2-ol as light brown oil; HPLC/MS 1.47 mm (B), [M-N2-OH] 132. 1H NMR (400 MHz, DMSO-d6) 6 7.49 (d, J = 8.4 Hz, 2H), 7.04 (d, J = 8.4 Hz,2H), 5.01 (s, 1H), 1.41 (s, 6H)

With the rapid development of chemical substances, we look forward to future research findings about 2077-19-2.

Reference:
Patent; MERCK PATENT GMBH; DORSCH, Dieter; MUZERELLE, Mathilde; BURGDORF, Lars; WUCHERER-PLIETKER, Margarita; CZODROWSKI, Paul; ESDAR, Christina; (278 pag.)WO2017/121444; (2017); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Reference of 2077-19-2, With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, molecular weight is 215.09, as common compound, the synthetic route is as follows.

General procedure: General Procedure C: To vial equipped with a stir bar and placed under argon atmosphere was added N- ((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)-lH-indazol-7-yl)-4-oxo-7-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide (1 equiv, typically 25-50 mg), the appropriate aryl halide/heteroaryl halide (3 equiv), potassium acetate (2.6 equiv) and Pd(PPh3)4 (0.2 equiv). The vial was sealed with a septum capped. To the vial was added l,4-dioxane:water (4: 1) to afford a reaction volume 0.05M in boronic ester. The reaction solution was degassed with argon. The reaction mixture was stirred at 90 C for 5h or l6h. Upon cooling to ambient temperature, the reaction mixture was concentrated in vacuo and the resulting residue was subjected to HPLC purification to afford the indicated product. Alternately, (S)-2-(3-cyclopropyl-lH-pyrazol-l-yl)-N-(2-(3,5-difluorophenyl)-l-(3-(4- (morpholinosulfonyl)phenyl)-4-oxo-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4- dihydroquinazolin-2-yl)ethyl)acetamide or 2-((3bR,4aS)-3-(difluoromethyl)-5,5-difluoro- 3b,4,4a,5-tetrahydro-lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)-N-((S)-2-(3,5- difluorophenyl)- 1 -(3 -(4-(morpholinosulfonyl)phenyl)-4-oxo-7 -(4,4,5,5 -tetramethyl- 1,3,2- dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)ethyl)acetamide may be substituted for N- ((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)-lH-indazol-7-yl)-4-oxo-7-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide. Example 18: Preparation of N-((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)-lH- indazol-7-yl)-7-(4-(2-hydroxypropan-2-yl)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2- (3,5-difhiorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5- tetrahydro- lH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol- 1 -yl)acetamide The title compound was prepared according to General Procedure C using 2-(4- bromophenyl)propan-2-ol as the coupling partner. Specific details are provided as a representative example of this general procedure. To a 1 dram vial equipped with a stir bar was added N-((S)- 1 -(3 -(4-chloro- 1 -methyl-3 -(methylsulfonamido)- lH-indazol-7 -yl)-4- oxo-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5- difhiorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difhioro-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide (40 mg, 0.043 mmol), 2-(4- bromophenyl)propan-2-ol (27.7 mg, 0.129 mmol), potassium acetate (10.96 mg, 0.112 mmol) and Pd(Ph3P)4 (9.93 mg, 8.59 pmol). The vial was capped with a septum cap and then placed under argon atmosphere (vac/fill x 3). To the vial was added dioxane (687 pl) and water (172 m). The reaction mixture was degassed (vac/fill with argon x 3, the solvent boils slightly under brief vacuum). The reaction mixture was stirred at 90 C for 5 hr. Upon cooling to room temperature, the contents of the vial were transferred to a 20 mL scintillation vial with the aid of DCM and then was concentrated in vacuo using a Biotage V10 evaporator. The residue was then taken up in DMF (1.5 mL) and then filtered through a syringe filter. The filtrate was subjected to HPLC purification with the following conditions: Column = Zorbax Eclipse Plus C 18, 21.2 x 100 mm, 5 pm particles; Solvent A = 0.1% Formic Acid in 100% Water. Solvent B = Acetonitrile. Flow Rate = 40 mL/min. Start % B = 53.2 Final % B = 73.2. Gradient Time = 7 min, then a 2 min hold at 98% B. Wavelength = 215 and 254 nm. ESI+ Range: 150 to 1500 dalton. Sample was loaded at 30% B. This purification afforded N-((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)- lH-indazol-7-yl)-7-(4-(2-hydroxypropan-2-yl)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)- 2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5- tetrahydro-lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide (9.9 mg, 25 % yield, 100% purity). The sample was analyzed using LCMS Method D: retention time = 2.45 min.; observed ion = 939.2 (M+H). 1H NMR (METHANOL-d4, 500 MHz) d 8.35 (d,1H, J=7.9 Hz), 8.13 (s, 1H), 7.96 (br d, 1H, J=8.2 Hz), 7.81 (br d, 2H, J=7.9 Hz), 7.71 (d, 2H, J=8.2 Hz), 7.31 (br d, 1H, J=7.6 Hz), 7.20 (d, 1H, J=7.6 Hz), 6.8-6.8 (m, 1H), 6.63 (br d, 2H, J=6.7 Hz), 4.9-4.9 (m, 1H), 4.55 (d, 2H, J=4.0 Hz), 3.63 (s, 3H), 3.5-3.5 (m, 1H),3.4-3.4 (m, 1H), 3.2-3.3 (m, 3H), 3.12 (br dd, 1H, J=9.2, 14.0 Hz), 2.4-2.5 (m, 2H), 1.63 (s, 6H), 1.36 (br d, 1H, J=6. l Hz), 1.01 (br s, 1H)

Statistics shows that 2077-19-2 is playing an increasingly important role. we look forward to future research findings about 2-(4-Bromophenyl)propan-2-ol.

Reference:
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BELEMA, Makonen; BENDER, John A.; FRENNESSON, David B.; GILLIS, Eric P; IWUAGWU, Christiana; KADOW, John F; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M.; RAJAMANI, Ramkumar; SAULNIER, Mark G.; WANG, Alan Xiangdong; (313 pag.)WO2019/198024; (2019); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Reference of 2077-19-2, With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, molecular weight is 215.09, as common compound, the synthetic route is as follows.

General procedure: General Procedure C: To vial equipped with a stir bar and placed under argon atmosphere was added N- ((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)-lH-indazol-7-yl)-4-oxo-7-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide (1 equiv, typically 25-50 mg), the appropriate aryl halide/heteroaryl halide (3 equiv), potassium acetate (2.6 equiv) and Pd(PPh3)4 (0.2 equiv). The vial was sealed with a septum capped. To the vial was added l,4-dioxane:water (4: 1) to afford a reaction volume 0.05M in boronic ester. The reaction solution was degassed with argon. The reaction mixture was stirred at 90 C for 5h or l6h. Upon cooling to ambient temperature, the reaction mixture was concentrated in vacuo and the resulting residue was subjected to HPLC purification to afford the indicated product. Alternately, (S)-2-(3-cyclopropyl-lH-pyrazol-l-yl)-N-(2-(3,5-difluorophenyl)-l-(3-(4- (morpholinosulfonyl)phenyl)-4-oxo-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4- dihydroquinazolin-2-yl)ethyl)acetamide or 2-((3bR,4aS)-3-(difluoromethyl)-5,5-difluoro- 3b,4,4a,5-tetrahydro-lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)-N-((S)-2-(3,5- difluorophenyl)- 1 -(3 -(4-(morpholinosulfonyl)phenyl)-4-oxo-7 -(4,4,5,5 -tetramethyl- 1,3,2- dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)ethyl)acetamide may be substituted for N- ((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)-lH-indazol-7-yl)-4-oxo-7-(4,4,5,5- tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5- difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide. Example 18: Preparation of N-((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)-lH- indazol-7-yl)-7-(4-(2-hydroxypropan-2-yl)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2- (3,5-difhiorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5- tetrahydro- lH-cyclopropa[3,4]cyclopenta[1,2-c]pyrazol- 1 -yl)acetamide The title compound was prepared according to General Procedure C using 2-(4- bromophenyl)propan-2-ol as the coupling partner. Specific details are provided as a representative example of this general procedure. To a 1 dram vial equipped with a stir bar was added N-((S)- 1 -(3 -(4-chloro- 1 -methyl-3 -(methylsulfonamido)- lH-indazol-7 -yl)-4- oxo-7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-3,4-dihydroquinazolin-2-yl)-2-(3,5- difhiorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difhioro-3b,4,4a,5-tetrahydro- lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide (40 mg, 0.043 mmol), 2-(4- bromophenyl)propan-2-ol (27.7 mg, 0.129 mmol), potassium acetate (10.96 mg, 0.112 mmol) and Pd(Ph3P)4 (9.93 mg, 8.59 pmol). The vial was capped with a septum cap and then placed under argon atmosphere (vac/fill x 3). To the vial was added dioxane (687 pl) and water (172 m). The reaction mixture was degassed (vac/fill with argon x 3, the solvent boils slightly under brief vacuum). The reaction mixture was stirred at 90 C for 5 hr. Upon cooling to room temperature, the contents of the vial were transferred to a 20 mL scintillation vial with the aid of DCM and then was concentrated in vacuo using a Biotage V10 evaporator. The residue was then taken up in DMF (1.5 mL) and then filtered through a syringe filter. The filtrate was subjected to HPLC purification with the following conditions: Column = Zorbax Eclipse Plus C 18, 21.2 x 100 mm, 5 pm particles; Solvent A = 0.1% Formic Acid in 100% Water. Solvent B = Acetonitrile. Flow Rate = 40 mL/min. Start % B = 53.2 Final % B = 73.2. Gradient Time = 7 min, then a 2 min hold at 98% B. Wavelength = 215 and 254 nm. ESI+ Range: 150 to 1500 dalton. Sample was loaded at 30% B. This purification afforded N-((S)-l-(3-(4-chloro-l-methyl-3-(methylsulfonamido)- lH-indazol-7-yl)-7-(4-(2-hydroxypropan-2-yl)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)- 2-(3,5-difluorophenyl)ethyl)-2-((3bS,4aR)-3-(difluoromethyl)-5,5-difluoro-3b,4,4a,5- tetrahydro-lH-cyclopropa[3,4]cyclopenta[l,2-c]pyrazol-l-yl)acetamide (9.9 mg, 25 % yield, 100% purity). The sample was analyzed using LCMS Method D: retention time = 2.45 min.; observed ion = 939.2 (M+H). 1H NMR (METHANOL-d4, 500 MHz) d 8.35 (d,1H, J=7.9 Hz), 8.13 (s, 1H), 7.96 (br d, 1H, J=8.2 Hz), 7.81 (br d, 2H, J=7.9 Hz), 7.71 (d, 2H, J=8.2 Hz), 7.31 (br d, 1H, J=7.6 Hz), 7.20 (d, 1H, J=7.6 Hz), 6.8-6.8 (m, 1H), 6.63 (br d, 2H, J=6.7 Hz), 4.9-4.9 (m, 1H), 4.55 (d, 2H, J=4.0 Hz), 3.63 (s, 3H), 3.5-3.5 (m, 1H),3.4-3.4 (m, 1H), 3.2-3.3 (m, 3H), 3.12 (br dd, 1H, J=9.2, 14.0 Hz), 2.4-2.5 (m, 2H), 1.63 (s, 6H), 1.36 (br d, 1H, J=6. l Hz), 1.01 (br s, 1H)

Statistics shows that 2077-19-2 is playing an increasingly important role. we look forward to future research findings about 2-(4-Bromophenyl)propan-2-ol.

Reference:
Patent; VIIV HEALTHCARE UK (NO.5) LIMITED; BELEMA, Makonen; BENDER, John A.; FRENNESSON, David B.; GILLIS, Eric P; IWUAGWU, Christiana; KADOW, John F; NAIDU, B. Narasimhulu; PARCELLA, Kyle E.; PEESE, Kevin M.; RAJAMANI, Ramkumar; SAULNIER, Mark G.; WANG, Alan Xiangdong; (313 pag.)WO2019/198024; (2019); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Synthetic Route of 2077-19-2, With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, molecular weight is 215.09, as common compound, the synthetic route is as follows.

Example 2: Synthesis of 1-bromo-4-(1-methoxy-1-methyl-ethyl)-benzene:A mixture of 6.87 g of ethyl 4-bromobenzoate (10) was allowed to react with 64 mL(1.4 M in toluene) of methyl magnesium bromide in THF at -4O0C for 1 hour, and the reaction mixture was gradually warmed to O0C. The reaction was quenched with saturated aqueous ammonium chloride solution and the resultant mixture was extracted with ethyl acetate. The organic layer was washed with brine, was dried over magnesium sulfate, was filtered, and the solvent was removed in vacuo. Purification by silica gel chromatography (50:1 to 10:1 EPO hexanes-ethyl acetate) afforded 6.44 g (99% yield) of 2-(4-bromophenyl)propan-2-o1 ; MS (AP/CI) observed: 199.1 (M+H – H2O)+, 100%; 213.1 , 215.1 (M-H)”, 60%, 80%. 2-(4- Bromophenyl)propan-2-o1 (1.77 g) and iodomethane (1.16 g) in THF (100 mL) were treated with sodium hydride, 60% in mineral oil (328 mg). After stirring for 24 h at room temperature, the reaction mixture was quenched with dilute aqueous hydrochloric acid, was extracted with ethyl acetate, and the organic layer was washed with brine, was dried over magnesium sulfate, was filtered, and the solvent was removed in vacuo. The resultant oil was purified by silica gel chromatography (200:1 hexanes-ethylacetate) to afford 0.5 g of 1-bromo-4-(1- methoxy-1-methyl-ethyl)-benzene; 13C NMR (400 MHz, CDCI3) delta 145.35, 131.53, 127.91 , 121.00, 50.90, 28.60.

Statistics shows that 2077-19-2 is playing an increasingly important role. we look forward to future research findings about 2-(4-Bromophenyl)propan-2-ol.

Reference:
Patent; PFIZER PRODUCTS INC.; WO2006/75226; (2006); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Application of 2077-19-2, With the rapid development and complex challenges of chemical substances, the synthesis of new drugs is usually one of the most effective ways to increase yield.2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, molecular weight is 215.09, as common compound, the synthetic route is as follows.

[0168] A mixture of 2-( 4-bromophenyl)propan-2-ol (2.80g, 13.0 mmol), 4,4,4′,4′,5,5,5′,5′-octamethyl-2,2′-bi(1,3,2-dioxaborolane)(3.30 g, 13.0 mmol),AcOK (2.60 g, 26.0mmol)and Pd(dppf)Cl2 (476 mg, 0.65 mmol) in dioxane (60 mL)was stirred at 80 C. for2 hrs underN2 .After HPLC and TLC(PE:Et0Ac=3: 1) showed the reaction was complete, the mixturewas concentrated and purified by MPLC to give the titlecompound (2.00 g, yield: 58.8%) as a white solid.

Statistics shows that 2077-19-2 is playing an increasingly important role. we look forward to future research findings about 2-(4-Bromophenyl)propan-2-ol.

Reference:
Patent; BLUEPRINT MEDICINES CORPORATION; Hodous, Brian L.; (150 pag.)US2016/31892; (2016); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Reference of 2077-19-2, Adding some certain compound to certain chemical reactions, such as: 2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol,molecular formula is C9H11BrO, can increase the reaction rate and produce products with better performance than those obtained under traditional synthetic methods. Here is a downstream synthesis route of the compound 2077-19-2.

In a 250ml 2 necked round-bottom flask equipped with a condenser and under argon were dissolved 5.3g of N4,N4′-di(naphthalen-1 -yl)-N4,N4′- diphenylbiphenyl-4,4′-diamine (NPD) and 4.2g of 2(4-bromophenyl-2- propanol) in 65ml of dichloromethane. Then 3.15ml of BF3, Et.20 were added dropwise under stirring at room temperature. The reaction was monitored by thin layer chromatography (TLC). After completion, the reaction medium was filtered through a silica gel plug. The plug was rinsed by 25ml of dichloromethane. After removal of the solvent under reduced pressure crude product was recovered and purified by flash chromatography over silica gel using a mixture of 50/50 v/v hexane/dichloro methane as the eluent. 8.1 g of pure N4,N4′-bis(4-(2-(4- bromophenyl)propan-2-yl)phenyl)-N4,N4′-di(naphthalen-1 -yl)biphenyl-4,4′- diamine was obtained. Structure was confirmed by NMR.

According to the analysis of related databases, 2077-19-2, the application of this compound in the production field has become more and more popular.

Reference:
Patent; SOLVAY SA; CAILLE, Jean, Raphael; MAUNOURY, Jonathan; WO2013/98175; (2013); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

As we all know, there are many different methods for the synthesis of a compound, and people can choose the synthesis method that suits their own laboratory according to the actual situation. 2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, The compound is widely used in many fields, so it is necessary to find a new synthetic route. The downstream synthesis method of this compound is introduced below. Safety of 2-(4-Bromophenyl)propan-2-ol

Step 1: 5-Amino-1-(2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-carbonitrile from step 1, example 15 (500 mg, 2.1 mmol), 2-(4-bromophenyl)propan-2-ol (519 mg, 2.41 mmol), and cesium carbonate (1.03 g, 3.15 mmol) were taken up anhydrous toluene (14 ml). The mixture was degassed with argon and bis(tri-tert-butylphosphine)palladium (107 mg, 0.21 mmol) was added. The mixture was again degassed with argon and then stirred under argon at 120 C. for 4.5 hours. Additional 2-(4-bromophenyl)propan-2-ol (50 mg) was added and the mixture heated for 2 more hours. The material was cooled to ambient and stirred overnight. The crude was filtered through a plug of celite, rinsing well with ethyl acetate (60 ml). The organic layer was shaken with water (60 ml) in a separatory funnel and collected. The aqueous phase was back extracted with ethyl acetate (2×40 ml). The combined organic phase was dried with magnesium sulfate, filtered and stripped. The remainder was purified through Analogix flash column chromatography using ethyl acetate in hexanes (10% to 45% gradient, 23 g silica gel) to provide 5-(4-(2-hydroxypropan-2-yl)phenylamino)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazole-4-carbonitrile as a red-brown viscous oil (482 mg, 62% yield). LC/MS calc’d for C19H28N4O2Si (m/e) 372.55, obs’d 371 (M-H, ES-).

With the rapid development of chemical substances, we look forward to future research findings about 2077-19-2.

Reference:
Patent; Billedeau, Roland Joseph; Kondru, Rama K.; Lopez-Tapia, Francisco Javier; Lou, Yan; Owens, Timothy D.; Qian, Yimin; So, Sung-Sau; Thakkar, Kshitij C.; Wanner, Jutta; US2012/295885; (2012); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

Reference of 2077-19-2 , The common heterocyclic compound, 2077-19-2, name is 2-(4-Bromophenyl)propan-2-ol, molecular formula is C9H11BrO, its traditional synthetic route has been very mature, but the traditional synthetic route has various shortcomings, such as complicated route, low yield, poor purity, etc., below Introduce a new synthetic route.

[0001247] A mixture of 2-(4-bromophenyl)propan-2-ol (34 mg, 0.15 mmol), Compound 356A (75 mg, 0.15 mmol), [l, -bis(diphenylphosphino)ferrocene]dichloropalladium(II) (7 mg, 8.2 muiotaetaomicron), sodium carbonate (44 mg, 0.30 mmol), water (0.5 mL), and 1,4-dioxane (5 mL) was stirred under nitrogen atmosphere at 80 C for 2 h. After cooling, the reaction mixture was treated with water (5 mL), extracted with ethyl acetate (10 mL x 3), washed with brine (5 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified with prep-HPLC. The solution was adjusted to pH = 8.0 with sodium bicarbonate solution, extracted with ethyl acetate (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and concentrated to furnish Compound 356. LC-MS (ESI) m/z: 563 [M+H]+; 1H-NMR (CDCI3, 400 MHz): delta (ppm) 1.42-1.75 (m, 6H), 1.79-1.86 (m, 4H), 2.74-2.81 (m, 4H), 2.96-3.04 (m, 2H), 4.24-4.31 (m, 6H), 5.05 (d, J= 2.4 Hz, 1H), 6.70-6.76 (m, 2H), 7.39 (d, J= 8.8 Hz, 1H), 7.75-7.64 (m, 5H), 7.68 (d, J= 9.2 Hz, 2H), 8.31 (d, J= 8.8 Hz, 2H).

The synthetic route of 2077-19-2 has been constantly updated, and we look forward to future research findings.

Reference:
Patent; BIOMARIN PHARMACEUTICAL INC.; WANG, Bing; CHU, Daniel; BRIDGES, Alexander, James; WO2015/42397; (2015); A1;,
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts